Therini Bio announced the first patient dosing in a Phase 1b trial of THN391, a novel anti-inflammatory monoclonal antibody targeting fibrin for diabetic macular edema treatment. The company also advanced THN622, a fibrin/VEGF bispecific antibody, as a potential new standard of care for retinal neurodegeneration. Initial trial data is expected in Q4 2026.

Recursion Pharmaceuticals, an AI-focused biotech company, has hit a 52-week low despite partnerships with major pharmaceutical companies and Nvidia. While the company's AI-powered drug discovery platform shows promise and addresses a real problem in drug development costs and timelines, it lacks tangible clinical evidence. With no approved products and only early-stage pipeline candidates, the stock remains highly speculative and risky for most investors.

Sanofi is highlighted as an attractive growth stock in the healthcare sector trading at a low valuation. With a market cap of $100 billion, the company has a pipeline of 75+ projects including 34 in late-stage development. Despite strong Q1 2026 sales growth of 14% and Dupixent sales up 31%, the stock has declined 11% this year. Trading at a forward P/E of less than 9 (vs S&P 500 average of 22) and offering a 5.7% dividend yield, the article suggests it presents a good margin of safety for long-term investors.

The article highlights three European dividend stocks offering yields significantly higher than the S&P 500 average of 1.2%. Shell (SHEL) benefits from high oil prices and strategic transformation, Unilever (UL) demonstrates strong brand power with 43 consecutive years of dividend increases, and Sanofi (SNY) shows robust pharmaceutical growth with 30 consecutive years of dividend increases.

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

The complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from major pharmaceutical companies are expected to expand treatment options across multiple indications including PNH, aHUS, CIDP, and IgAN.

Sanofi's shareholders approved all resolutions at the April 29, 2026 Annual General Meeting, including the appointment of Belén Garijo as Chief Executive Officer effective May 1, 2026. The company approved a €4.12 per share dividend and welcomed Christel Heydemann (CEO of Orange) as an independent board member. Garijo, a physician with extensive experience at Merck and previous roles at Sanofi, will lead the company's transformation focusing on execution discipline and capital allocation.

Sanofi's Annual General Meeting approved the appointment of Belén Garijo as Board Administrator and Chief Executive Officer, effective May 1, 2026. The meeting also approved the 2025 financial statements, a dividend of €4.12 per share, and welcomed Christel Heydemann (Orange CEO) as an independent board member. Garijo, a physician with extensive experience at Merck and previous roles at Sanofi, will lead the company's next development phase with focus on execution discipline and capital allocation.

Eli Lilly's retatrutide achieved 28.7% mean weight loss in April 2026, matching bariatric surgery outcomes as the first non-surgical therapy to do so. However, the competitive landscape is shifting from drug development capability to intellectual property control and real-world efficacy. Multiple companies including Novo Nordisk, Pfizer, Hanmi, and others are advancing triple-agonist programs, with Sanofi holding the largest IP position with 27 programs. The report highlights that the true battleground will be navigating IP structures and closing the gap between trial results and actual patient outcomes.

Three mega-cap companies announced significant dividend increases: Costco raised its quarterly dividend by 13% to $1.47, Sanofi increased its dividend by 19% to $2.42 per depository receipt, and SAP boosted its dividend by approximately 15% to $2.93 per depository receipt. Despite varying stock performance, all three companies continue to return capital to shareholders.